drugset / Trial / NCT00761514

Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira

NCT00761514

Phase 4 Terminated 14 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate quality of life changes in Puerto Rican subjects with Rheumatoid Arthritis treated with Humira (adalimumab) as their first Anti-TNF Monoclonal Antibody.

Timeline

Start
2006-11
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg

Indications